Michael Ohliger
Modality Director for MRI · University of California (San Francisco) School of Medicine
Credentials: · · · · ·
History
Massachusetts Institute of Technology Harvard/MIT Division
- 2003–2007
Research
Hyperpolarized 13C MRI: State of the Art and Future Directions
Review · Radiology · 2019 · 263 citations
Systematic review or meta-analysis · Radiology · 2018 · 240 citations
Calibrationless parallel imaging reconstruction based on structured low-rank matrix completion
Magnetic Resonance in Medicine · 2014 · 216 citations
22 papers · 8 as a resident
19 papers
- ZW
16 papers
14 papers
11 papers · 10 as a resident
10 papers · 5 as a resident
9 papers
7 papers
Grants
- 2024–2029
Chemoenzymatic Radiosyntheses of [18F]FDG-Derived Oligosaccharides for S. aureus Detection
National Institute of Allergy and Infectious Diseases · R01
PI · $2.3M · University of California, San Francisco
- 2021–2026
Sensing Living P. aeruginosa Using D-Alanine Derived Radiotracers
National Institute of Biomedical Imaging and Bioengineering · R01
PI · $2.7M · University of California, San Francisco
- 2018–2025
Novel Hyperpolarized 13C Molecular Imaging Techniques for Differentiating NAFLD and NASH
National Institute of Diabetes and Digestive and Kidney Diseases · R01
Contact PI · $2.1M · University of California, San Francisco
- 2017–2023
Clinical Translation of D-Amino Acid Derived PET Tracers for Imaging Spinalinfection
National Institute of Biomedical Imaging and Bioengineering · R01
PI · $2.2M · University of California, San Francisco
Clinical trials
- 2020–2025
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
Principal investigator · Completed
Michael Ohliger, MD PhD
- 2018–2022
68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
Principal investigator · Completed
University of California, San Francisco